These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15307833)

  • 21. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
    Mielcarek M; Martin PJ; Leisenring W; Flowers ME; Maloney DG; Sandmaier BM; Maris MB; Storb R
    Blood; 2003 Jul; 102(2):756-62. PubMed ID: 12663454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
    Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
    Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy.
    Weisdorf DJ; Snover DC; Haake R; Miller WJ; McGlave PB; Blazar B; Ramsay NK; Kersey JH; Filipovich A
    Blood; 1990 Aug; 76(3):624-9. PubMed ID: 2378989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exfoliative rejection after intestinal transplantation in children.
    Ishii T; Mazariegos GV; Bueno J; Ohwada S; Reyes J
    Pediatr Transplant; 2003 Jun; 7(3):185-91. PubMed ID: 12756042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease.
    Landfried K; Bataille F; Rogler G; Brenmoehl J; Kosovac K; Wolff D; Hilgendorf I; Hahn J; Edinger M; Hoffmann P; Obermeier F; Schoelmerich J; Andreesen R; Holler E
    Clin Exp Immunol; 2010 Jan; 159(1):87-92. PubMed ID: 19912254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macrochimerism in Intestinal Transplantation: Association With Lower Rejection Rates and Multivisceral Transplants, Without GVHD.
    Zuber J; Rosen S; Shonts B; Sprangers B; Savage TM; Richman S; Yang S; Lau SP; DeWolf S; Farber D; Vlad G; Zorn E; Wong W; Emond J; Levin B; Martinez M; Kato T; Sykes M
    Am J Transplant; 2015 Oct; 15(10):2691-703. PubMed ID: 25988811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital.
    Chang HK; Kim SY; Kim JI; Kim SI; Whang JK; Choi JY; Park JM; Jung ES; Rha SE; Kim DG; Moon IS; Lee MD
    Transplant Proc; 2016 Mar; 48(2):473-8. PubMed ID: 27109981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children.
    Patey-Mariaud de Serre N; Reijasse D; Verkarre V; Canioni D; Colomb V; Haddad E; Brousse N
    Bone Marrow Transplant; 2002 Feb; 29(3):223-30. PubMed ID: 11859394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation.
    Koehler MT; Howrie D; Mirro J; Neudorf S; Blatt J; Corey S; Wollman M; Kelly-Ekeroth V; Reyes J
    Bone Marrow Transplant; 1995 Jun; 15(6):895-9. PubMed ID: 7581088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Belgian multicenter experience with intestinal transplantation.
    Ceulemans LJ; Monbaliu D; De Roover A; Detry O; Troisi RI; Rogiers X; Reding R; Lerut JP; Ysebaert D; Chapelle T; Pirenne J
    Transpl Int; 2015 Dec; 28(12):1362-70. PubMed ID: 26033472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
    Nash RA; Antin JH; Karanes C; Fay JW; Avalos BR; Yeager AM; Przepiorka D; Davies S; Petersen FB; Bartels P; Buell D; Fitzsimmons W; Anasetti C; Storb R; Ratanatharathorn V
    Blood; 2000 Sep; 96(6):2062-8. PubMed ID: 10979948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus.
    Shapira MY; Resnick IB; Dray L; Aker M; Stepensky P; Elad S; Gesundeheidt B; Samuel S; Or R
    Cytotherapy; 2009; 11(1):61-7. PubMed ID: 19191054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.